Health Condition 1: D68- Other coagulation defects
Conditions
Interventions
Intervention1: Troylase 1NIH (Hemocoagulase 1NIH) Injection: Adults are given 1 ampoule of Troylase subcutaneously or intramuscularly and if blood loss is serious 1 ampoule intravenously and 1ampoule
Sponsors
Asian Institute of Gatroentrology
Eligibility
Inclusion criteria
Inclusion criteria: Bleeding Esophageal and / or Gastric varices
Exclusion criteria
Exclusion criteria: Contraindicated to undergo endoscopy, already hospitalized for another illness Pregnant or lactating Patients with altered post-surgical anatomy of the stomach Patient treated by other endoscopic or surgical modalities within 7 days prior to the intended application of Troylase
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients with acute (procedural) hemostasis in 24 hour period, and the rate of recurrent bleeding within 72 hours of treatmentTimepoint: 24 hr and 72 hr | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of all Adverse Events (AEs), non-serious and serious, possibly related to or related to the procedure and/or drug that are experienced by study participantsTimepoint: 24 hr and 72 hr | — |
Countries
India
Contacts
Public ContactDr Manu Tandon
Asian Institute of Gastroentrology
Outcome results
None listed